Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06365060 · ClinicalTrials.gov registry record
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
A clinical trial of Smoldering Multiple Myeloma, sponsored by Tufts Medical Center.
- Recruiting
- Registry status
- 400
- Enrollment target
- 13
- Study locations
NCT06365060 is a study of Smoldering Multiple Myeloma that is actively recruiting participants, run by Tufts Medical Center. The registered enrollment target is 400 participants, below the 780-participant average among 20 other Smoldering Multiple Myeloma trials with a reported enrollment target (49% lower). The trial reports 13 study locations across 10 states.
The verdict
NCT06365060, a study of Smoldering Multiple Myeloma, is actively recruiting participants, sponsored by Tufts Medical Center.
- RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 13
- Study locations
Study Summary
In this multicenter study, we will recruit 400 patients 40 years of age or older at 15 centers with a diagnosis of smoldering multiple myeloma (SMM), a group of patients for whom standard of care is observation not treatment. The main goal of this study is to screen for the diagnosis of light-chain amyloidosis (AL) before the onset of symptomatic disease and to develop a training set for a likelihood algorithm.
Conditions Studied
Study Locations (13)
California
- Cedars-Sinai Medical Center - Los Angeles
- University of California, San Francisco - San Francisco
New York
- Columbia University Irving Medical Center - New York
- Memorial Sloan Kettering Cancer Center - New York
North Carolina
- Atrium Health Levine Cancer Institute - Charlotte
- UNC Lineberger Comprehensive Cancer Center - Durham
Alabama
- University of Alabama Hospital - Birmingham
Florida
- Cleveland Clinic Florida, Weston Hospital - Weston
Massachusetts
- Tufts Medical Center - Boston
Ohio
- The Ohio State University Comprehensive Cancer Center - Columbus
Texas
- UT Southwestern, Harold C. Simmons Comprehensive Cancer Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2024-05-01 |
| Est. Completion | 2029-02-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06365060
The ClinicalTrials.gov registry entry for NCT06365060 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 780-participant average among 20 other Smoldering Multiple Myeloma trials with a reported enrollment target (49% lower). The listed sponsor is Tufts Medical Center, which has 169 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Smoldering Multiple Myeloma appearing as the primary indexed condition, and to 0 interventions.
NCT06365060 reports 13 study locations spanning 10 distinct geographic areas - top geographies include California, New York, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06365060 about?
NCT06365060 is a clinical study titled "Screening for AL Amyloidosis in Smoldering Multiple Myeloma". In this multicenter study, we will recruit 400 patients 40 years of age or older at 15 centers with a diagnosis of smoldering multiple myeloma (SMM), a group of patients for whom standard of care is observation not treatment. The main goal of this study is to screen for the diagnosis of light-chain ...
What is the current status of trial NCT06365060?
This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2024-05-01. Estimated completion is 2029-02-27.
What conditions does trial NCT06365060 study?
This clinical trial studies the following conditions: Smoldering Multiple Myeloma.
Who is sponsoring clinical trial NCT06365060?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06365060 being conducted?
This trial has 13 study locations across Alabama, California, Florida, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoldering Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
RECRUITING · Phase 2
-
Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial
RECRUITING
-
Registry for Adults With Plasma Cell Disorders (PCD's)
RECRUITING
-
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
RECRUITING · Phase 2
-
A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
RECRUITING · NA
-
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.